[Evaluation of Owren's thrombotest in the monitoring of treatment with antivitamin K].
The need to standardize the monitoring of oral anticoagulant treatments has led some countries to adopt, generally, Owren's Thrombotest. Apart from needing only one reagent and being perfectly adapted to this type of monitoring, the thrombotest has the advantage of being able to be used on capillary blood and venous blood and of not being influenced by the storage of the blood samples. Its disadvantages are that it is slow to perform, difficult to automate and that it has a therapeutic range which is narrow and close to the limits of precision of the technique. The results of the Thrombotest correlate well with those of the Quick test, the activated cephalin time and the X level measured by the amidolytic technique. Until the chromogenic assays are developed, the Owren's Thrombotest provides a better homogeneity and standardization of the results coming from different laboratories.
D000925:Anticoagulants / Q000627:therapeutic use*; D001780:Blood Coagulation Tests / Q000379:methods*; D005069:Evaluation Studies as Topic; D006801:Humans; D014812:Vitamin K / Q000037:antagonists & inhibitors*
D000925:Anticoagulants; D014812:Vitamin K
Evaluation du thrombotest d'Owren dans la surveillance des traitements par antivitamine K.